Related Experiment Videos
An MRI/US/x-ray compatible breast localization marker: in vivo evaluation.
Yangmei Li1, Claire M B Holloway, Carrie M Purcell
1Imaging Research, Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, Ontario M4N 3M5, Canada.
Academic Radiology
|December 3, 2005
Summary
A new trimodality breast localization marker showed excellent biocompatibility and stability in vivo for up to 7 weeks. This imaging marker is a promising alternative to traditional wire localization for breast biopsy procedures.
Area of Science:
- Biomedical Engineering
- Radiology
- Surgical Oncology
Background:
- Traditional wire localization for breast biopsy can be uncomfortable and may lead to complications.
- A novel trimodality marker offers potential for improved breast lesion localization.
- In vivo evaluation is crucial to assess marker safety and efficacy.
Purpose of the Study:
- To evaluate the in vivo performance and biocompatibility of a new trimodality breast localization marker.
- To assess the marker's stability, imaging characteristics, and tissue response over time.
- To determine the marker's potential utility for human surgical biopsy localization.
Main Methods:
- A new trimodality marker was implanted in five rabbits.
- Marker placement and biopsies were performed under ultrasound (US) guidance.
- Magnetic resonance imaging (MRI), US, and x-ray were used to monitor the marker; histopathology assessed biocompatibility.
Main Results:
- The marker demonstrated clear and stable contrast across MRI, US, and x-ray for 7 weeks.
- Biocompatibility was confirmed, with initial inflammation resolving to stable fibrosis by 7 weeks.
- Minimal marker migration and mechanical stability were observed.
Conclusions:
- The new trimodality marker is biocompatible and remains stable in vivo for at least 7 weeks.
- The marker shows potential as a safe and effective alternative to wire localization for breast biopsy.
- Further in vivo human testing is warranted to confirm its clinical utility.